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Introduction {#sec1}
============

As one of the most widespread mosquito-borne flaviviruses, dengue virus (DENV) causes millions of dengue disease cases worldwide each year. Dengue diseases include dengue fever and the more severe dengue hemorrhagic fever or dengue shock syndrome ([@bib25]). It is commonly held that increased pro-inflammatory cytokines and chemokines induced by DENV constitute a "cytokine storm" that results in vascular permeability in patients with dengue hemorrhagic fever.

Zika virus (ZIKV), also a mosquito-transmitted flavivirus, has been identified as the pathogenic agent of the 2015 Brazilian epidemic of fetal microcephaly ([@bib50], [@bib40]). In a majority of cases, ZIKV infection of adults is asymptomatic or only results in mild symptoms. However, more severe neurological conditions such as Guillain-Barré syndrome may occur in rare cases. ZIKV infection of women during pregnancy is a major concern, as this can lead to fetal microcephaly and intrauterine growth restriction ([@bib50], [@bib40], [@bib32]). Clinical reports and experimental data have shown that ZIKV can infect fetal and adult neural stem cells ([@bib37], [@bib42], [@bib54]), damage testis ([@bib39], [@bib21]), and transmit sexually ([@bib43]), suggesting that the virus has likely developed strategies for crossing a number of physiological barriers, including the placental barrier, and possibly the blood-brain and blood-testis barriers as well. Despite being similar to ZIKV in both genome organization and geographic distribution, DENV has not been associated with trans-placental infection of fetuses in the decades of clinical observation ([@bib25]). Conversely, ZIKV has not been reported to cause hemorrhagic fever or shock syndrome even though it was discovered seven decades ago ([@bib50], [@bib40], [@bib32]).

Macrophages are one of the important cell types involved in dengue pathogenesis ([@bib25]). ZIKV has recently been reported to infect primary human placenta-specific macrophages, Hofbauer cells ([@bib48], [@bib29]), which are derived from villous mesenchymal stem cells early in pregnancy and from the recruited fetal monocytes later in pregnancy ([@bib11]). ZIKV also infects decidual macrophages ([@bib17]), which are specialized cells present in the maternal decidual tissue and play an immunosuppressive role in pregnancy to prevent rejection of the fetus ([@bib26], [@bib38], [@bib23]). However, the role of macrophages in ZIKV infection of healthy adults remains unclear. Tissue-resident macrophages are present throughout the body and derived from two distinct origins. The majority of resident macrophages in the healthy tissues are derived from yolk sac before the establishment of the blood circulation. Circulating monocytes can also be recruited into the tissues to replenish tissue macrophages under homeostatic and pathological conditions ([@bib56], [@bib47]).

Primary human monocyte-derived macrophages are a physiologically relevant cell model for studying blood-borne pathogens, but supply and donor variability are common issues. The isolation of yolk sac-derived tissue-resident macrophages poses an even more considerable technical challenge. Alternative approaches to model these macrophages will be of great value for studying macrophage-pathogen interactions.

Recent progress in stem cell research has opened up a new avenue for human disease modeling, including ZIKV infection ([@bib54]). In the current study, we apply human pluripotent stem cell (hPSC)-derived macrophages, which have been shown to developmentally resemble yolk sac-derived tissue-resident macrophages ([@bib55], [@bib7]), to investigate the role of human macrophages in ZIKV and DENV pathogenesis. We found that the infected macrophages exhibit differential responses to ZIKV and DENV, which provide a possible explanation for ZIKV persistence and dissemination in human tissues.

Results {#sec2}
=======

hPSC-Derived Macrophages Support Productive ZIKV and DENV Infection {#sec2.1}
-------------------------------------------------------------------

We first determined whether primary human monocyte-derived macrophages are permissive to ZIKV and DENV infection *in vitro*. We observed that human adult monocyte ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D)-derived macrophages ([Figure S1](#mmc1){ref-type="supplementary-material"}E) supported productive infection of DENV and two strains of ZIKV, an African strain MR766 (ZIKV^M^), and a clinical isolate PRVABC59 (ZIKV^PR^) from the 2015 Zika outbreak in Puerto Rico, with different cell size changes ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G), similar infection rates ([Figures S1](#mmc1){ref-type="supplementary-material"}H--S1J), and low levels of cell death ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2E).

We next generated macrophages from hPSCs, including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), to model ZIKV and DENV infection of yolk sac-derived tissue-resident macrophages. Both hESCs and hiPSCs were maintained in an undifferentiated state with high expression of the pluripotency markers, including *SOX2*, *OCT4*, and *SSEA4* ([Figure 1](#fig1){ref-type="fig"}A). To initiate differentiation, hPSCs were cultured in suspension to form spherical embryoid bodies (EBs) for 5--7 days ([Figures 1](#fig1){ref-type="fig"}B and 1C). Then large EBs were transferred into gelatin-coated plates and further differentiated by macrophage colony-stimulating factor 1 (CSF1) and interleukin-3 (IL-3). After around 15 days, the round-shaped monocyte-like cells were continuously released from the flatten EBs and suspended in the medium ([Figures 1](#fig1){ref-type="fig"}B and 1C). Monocyte-like cells collected from the culture medium supernatant were further differentiated into macrophages in the presence of CSF1 ([Figures 1](#fig1){ref-type="fig"}B and 1C). RNA sequencing results revealed that these cells highly expressed the defined markers of the mononuclear phagocyte system, including *CD163*, *CSF1R*, *CD68*, *SPI1* (*PU-1*), *CD4*, *CD14*, *CD163*, etc. ([Figure 1](#fig1){ref-type="fig"}D). Further analysis of the expressions of *CD14*, *CD163*, *CD11b*, and *CD68* by flow cytometry and immunostaining indicated the high purity of the differentiated macrophages ([Figures 1](#fig1){ref-type="fig"}E and 1F). In contrast to hPSCs, the resulting macrophages were able to ingest myelin debris isolated from the mouse brains, indicating that the hPSC-derived macrophages have the phagocytic capacity ([Figures 2](#fig2){ref-type="fig"}A and 2B). Furthermore, hPSC-derived macrophages secreted high levels of pro-inflammatory cytokine tumor necrosis factor alpha (TNF-α), C-C motif chemokine ligand 4 (CCL4), and C-X-C motif chemokine ligand 8 (CXCL8/IL-8) in response to lipopolysaccharide (LPS) stimulation with significant morphological change ([Figures 2](#fig2){ref-type="fig"}C--2E). To further test whether the innate immune programs are functional in hPSC- and primary human monocyte-derived macrophages, we treated these cells with LPS or poly(I:C) to activate Toll-like receptor 4 (TLR4) and the antiviral pattern recognition receptors TLR3 and RIG-I/MDA5, respectively. As shown in [Figure 2](#fig2){ref-type="fig"}F, the transcription of interferon-stimulated genes *MX1*, *IFI44*, *RSAD2*, and *OASL*, and pro-inflammatory cytokines IL-6 (*IL6*) and *TNF*, were strongly induced by LPS and poly(I:C), suggesting that antimicrobial signaling pathways are intact in these cells. Together, these data suggest that hPSCs are successfully differentiated into functional macrophages.Figure 1Directed Differentiation of Human Pluripotent Stem Cells into Macrophages(A) Immunostaining images of hESCs and hiPSCs showing the high expression of pluripotent markers *SOX2*, *OCT4*, and *SSEA4*. Scale bar, 50 μm.(B) Schematic diagram of macrophage differentiation from human pluripotent stem cells.(C) Phase contrast microscopy images of hiPSCs, embryoid bodies (EBs) formed from hiPSCs, flattened EBs (indicated with the black arrowhead), the surrounding monocytes (indicated with the white arrowhead), and macrophages at day 5. Scale bar, 50 μm.(D) Heatmap of the defined macrophage markers generated from the RNA sequencing analysis of primary human monocyte- and hPSC-derived macrophages and hESC-derived hepatocytes.(E) Flow cytometry analysis of *CD14*, *CD163*, and *CD11b* expression in hESC-derived macrophages at day 5.(F) Immunostaining images of day 5 hiPSC-derived macrophages and quantifications for the percentages of marker^+^ cells among the total number of cells stained by DAPI. n = 5 independent experiments; data are presented as mean ± SD. Scale bar, 50 μm.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.Figure 2Functional Analysis of Macrophages Derived from Human Pluripotent Stem Cells(A and B) Images of phagocytosis assay performed with hESCs, hESC-derived macrophages, hiPSCs and hiPSC-derived macrophages incubated with CFSE-labeled myelin debris and quantifications for the percentages of CFSE^+^ cells among the total cell populations. n = 3 independent experiments; data are presented as mean ± SD; ^∗∗∗^p \< 0.001; unpaired two-tailed Student\'s t tests. Scale bar, 50 μm.(C) ELISA analysis of the secretion of CCL4, CXCL8 and TNF-α from macrophages upon LPS (100 ng/mL) stimulation for 3 hr. n = 3 independent experiments; data are presented as mean ± SD; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; unpaired two-tailed Student\'s t tests.(D and E) Phase contrast images of macrophages treated with or without LPS in (C) and quantitative analysis of cell size changes. n = 5 independent experiments; data are presented as mean ± SD; ^∗^p \< 0.05; ^∗∗^p \< 0.01; unpaired two-tailed Student\'s t tests. Scale bar, 50 μm.(F) Quantitative analysis of interferon-stimulated genes and pro-inflammatory cytokines gene expression in primary monocyte- and hPSC-derived macrophages after LPS treatment (10 ng/mL) or poly(I:C) transfection (2 μg/mL) using lipofectamine for 12 hr.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We next infected hPSC-derived macrophages with ZIKV and DENV. Similar to primary human monocyte-derived macrophages, both hESC- and hiPSC-derived macrophages increased in cell size after exposure to DENV, compared with ZIKV exposure or mock treatment ([Figure 3](#fig3){ref-type="fig"}A). These macrophages were infected by both viruses with around 90% infection rate ([Figures 3](#fig3){ref-type="fig"}B and 3C). Furthermore, the continuous release of virus particles into the culture medium suggested the persistent and productive ZIKV and DENV infection of hPSC-derived macrophages ([Figure 3](#fig3){ref-type="fig"}D). Both ZIKV and DENV infections also responded to the treatment by two previously identified anti-ZIKV drugs ([@bib59]) ([Figure 3](#fig3){ref-type="fig"}E). Little to no infection was detected in hESCs and hiPSCs exposed to DENV or ZIKV with the same MOI (MOI = 10) ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B).Figure 3Productive ZIKV and DENV Infection of Human Pluripotent Stem Cell-Derived Macrophages(A) Phase contrast microscopy images of 2.5 × 10^5^ macrophages derived from hESCs and hiPSCs exposed to DENV, ZIKV^M^, and ZIKV^PR^ (MOI = 10) or mock treated at day 5 for 12 hr and quantitative analysis of cell size change. n = 5 independent experiments; data are presented as mean ± SD; ^∗∗∗^p \< 0.001; one-way ANOVA. Scale bar, 50 μm.(B and C) Immunostaining images of cell samples in (A) with virus infection for 24 hr and quantifications for infection rates. n = 5 independent experiments; data are presented as mean ± SD; n.s., not significant; one-way ANOVA. Scale bar, 50 μm.(D) Virus titers of the supernatants collected from DENV- and ZIKV^PR^-infected macrophages (MOI = 10).(E) Western blot analysis of the effect of niclosamide and PHA-690509 on ZIKV and DENV^PR^ infection of macrophages at day 5. hiPSC-derived macrophages were treated with niclosamide or PHA-690509 at the indicated concentrations for 1 hr before inoculation with ZIKV and DENV^PR^ (MOI = 10), and cells were harvested at 24 hr after infection for western blot analysis.See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"}.

ZIKV and DENV Infection Result in Different Migratory Capacity of Macrophages {#sec2.2}
-----------------------------------------------------------------------------

Macrophages are able to migrate within the tissues and this mobility may facilitate virus dissemination and barrier crossing. To explore the effect of DENV or ZIKV infection on macrophage migration, we performed a wound-healing assay following infection ([Figure 4](#fig4){ref-type="fig"}A). Without infection or LPS treatment, the macrophages migrated into and filled the wound gap within 24 hr after the cells were scraped off. Macrophages that were pre-exposed to ZIKV infection for 4 hr (MOI = 10) similarly migrated into and filled the wound gap within 24 hr, behaving essentially like mock-treated cells. In contrast, DENV-infected macrophages lost the migratory ability under the same conditions, similar to the cells treated with LPS ([Figures 4](#fig4){ref-type="fig"}B and 4C), which has been shown to induce macrophage activation and suppress migration ([@bib45], [@bib44], [@bib58], [@bib18]). To determine whether the migrating macrophages are infected by ZIKV or represent a bystander population of cells, we examined the macrophages that migrated into the wound gap by immunostaining. As shown in [Figure 4](#fig4){ref-type="fig"}B, ZIKV-infected macrophages retained the migratory ability after infection. To rule out cell death as a cause for the failure of DENV-infected cells to fill the gap, we performed terminal deoxynucleotidyl transferase dUTP nick end labeling assay, which confirmed that ZIKV and DENV infection induced apoptosis in less than 6% of the cells at 28 hr post-infection ([Figures 4](#fig4){ref-type="fig"}D and 4E), whereas the infection rates and cell viability were around 90% ([Figures 4](#fig4){ref-type="fig"}F and 4G).Figure 4The Impact of ZIKV and DENV Infection on Macrophage Migration(A) Schematic diagram of wound-healing assay.(B and C) Phase contrast microscopy and immunostaining images (B) of wound-healing assay performed with DENV-, ZIKV^M^-, and ZIKV^PR^ infected, LPS (5 ng/mL) or mock-treated day 5 hESC- and hiPSC-derived macrophages showing macrophages migration leading edges immediately after scratching (4 hr post-infection) and after 24 hr (28 hr post-infection) (MOI = 10). Migration ability was quantified by the percentage of wound closure after scratching (C). n = 5 independent experiments; data are presented as mean ± SD; ^∗∗∗^p \< 0.001; one-way ANOVA. Scale bars, 50 μm.(D--G) Immunostaining images (D) of macrophage samples in (B) with virus infection for 28 hr and quantifications for cell death rates (E), virus infection rates (F), and relative cell viability (G). n = 5 independent experiments; data are presented as mean ± SD; n.s., not significant; one-way ANOVA. Scale bars, 50 μm.

Distinct Macrophage Migratory Ability Correlates with Differential Induction of MIF Secretion {#sec2.3}
---------------------------------------------------------------------------------------------

To explore the mechanism for the different migratory capacities of macrophages infected by ZIKV and DENV, we examined the gene expression profiles in the mock- and virus-infected macrophages12 hr post-infection ([Tables S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, [S4](#mmc5){ref-type="supplementary-material"}, [S5](#mmc6){ref-type="supplementary-material"}, and [S6](#mmc7){ref-type="supplementary-material"}). Interestingly, macrophage migration inhibitory factor (MIF), a pivotal regulator of innate immunity and an inhibitor of macrophage migration ([@bib5], [@bib8]), was released at a high level from DENV-infected and LPS-treated macrophages ([Figure 5](#fig5){ref-type="fig"}A), which is consistent with the previous reports that DENV and LPS can strongly induce MIF expression ([@bib8], [@bib4], [@bib15]), and that LPS inhibits macrophage migration ([@bib58], [@bib18]). In contrast, macrophages secreted little MIF after ZIKV infection and mock treatment ([Figure 5](#fig5){ref-type="fig"}A). Quantitative gene expression analysis indicated that ZIKV inhibits MIF at the transcription level ([Figure 5](#fig5){ref-type="fig"}B). A similar result was also observed in primary monocyte-derived macrophages ([Figure S4](#mmc1){ref-type="supplementary-material"}). To further confirm the role of MIF in macrophage migration, we neutralized MIF in the DENV-infected macrophage cultures with anti-MIF antibody which has been shown to efficiently block the activity of MIF ([@bib28]). MIF-neutralizing antibody significantly improved the migratory capacity of DENV-infected macrophages ([Figures 5](#fig5){ref-type="fig"}C and 5D). In addition, exogenous MIF treatment of the mock- and ZIKV^PR^-infected macrophages resulted in impaired wound healing ([Figures 5](#fig5){ref-type="fig"}C and 5D), consistent with the migration inhibitory role of MIF ([@bib5], [@bib8]). MTT assay indicated that MIF does not significantly affect cell viability after 24 hr of treatment ([Figure S5](#mmc1){ref-type="supplementary-material"}). Taken together, these data suggest that different levels of MIF secretion from ZIKV- and DENV-infected macrophages correlate with distinct macrophage migratory abilities.Figure 5The Effect of MIF on Macrophage Migration(A) ELISA analysis of the concentrations of MIF in the supernatants collected from DENV-, ZIKV^M^-, and ZIKV^PR^-infected, or mock- and LPS (5 ng/mL)-treated macrophage cultures at 12 and 24 hr after scratching in the wound-healing assay (MOI = 10). n = 3 independent experiments; data are presented as mean ± SD; ^∗∗∗^p \< 0.001; one-way ANOVA.(B) Quantitative analysis of *MIF* gene expression in the DENV- and ZIKV^PR^-infected macrophages at 12 hr post-infection. n = 3 independent experiments; data are presented as mean ± SD; ^∗∗∗^p \< 0.001; one-way ANOVA.(C and D) Phase contrast microscopy images (C) of wound-healing assay performed with DENV- and ZIKV^PR^-infected (MOI = 10), or mock-treated macrophages with or without MIF (10 ng/mL), anti-MIF antibody (5 μg/mL) treatment. Cell migration was quantified by the percentage of wound closure after scratching (D). n = 3 independent experiments; data are presented as mean ± SD; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; one-way ANOVA. Scale bar, 50 μm.See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

ZIKV and DENV Infections Induce Different Levels of Cytokine and Chemokine Expression in Macrophages {#sec2.4}
----------------------------------------------------------------------------------------------------

Considering that MIF is a critical regulator of innate immune and inflammatory responses through the activation of macrophages and T cells and its gene expression is regulated by nuclear factor κB (NF-κB) signaling ([@bib8], [@bib57], [@bib35], [@bib33], [@bib13]), we next investigated macrophage immune response to ZIKV and DENV infection. DENV, but not ZIKV, infection dramatically increased RNA levels of pro-inflammatory cytokines and chemokines, including IL-1β (*IL1B*), *IL6*, *TNF*, macrophage inflammatory protein 1α (*MIP1A*/*CCL3*), macrophage inflammatory protein 1 β (*MIP1B*/*CCL4*) and *CXCL8*, in both monocyte- and hPSC-derived macrophages ([Figure 6](#fig6){ref-type="fig"}A). On the other hand, both viruses activated interferon-β1(*IFNB1*) expression similarly in each cell type ([Figure 6](#fig6){ref-type="fig"}A). In addition, both viruses similarly inhibited interferon-induced transmembrane protein 3 (*IFITM3*) expression in the infected macrophages, while *IFITM3* was highly induced in the uninfected cells by interferon paracrine in the same cell population ([Figure S6](#mmc1){ref-type="supplementary-material"}A), consistent with their ability to block interferon signaling by targeting STAT2 ([@bib3], [@bib22]). Further qPCR analysis indicated that other interferon-stimulated genes, including *IFITM1*, *IFIT1*, *MX1*, *IFI44*, and *RSAD2*, were also induced by both viruses in the whole cell population. Type 1 interferons, including *IFNA1* and *IFNA2*, were highly expressed, while type 2 interferon *IFNG*, which is predominantly produced by activated T cells and natural killer cells, was not induced in both virus-infected macrophages ([Figure S6](#mmc1){ref-type="supplementary-material"}B). All these data suggest that the lower pro-inflammatory cytokine/chemokine induction by ZIKV is not a result of general repression of gene activation.Figure 6Cytokine and Chemokine Expression in Macrophages Infected with ZIKV and DENV(A) qPCR analysis of cytokines and chemokines expression in DENV-, ZIKV^M^-, and ZIKV^PR^-infected, or mock-treated macrophages derived from primary human monocytes, hESCs or hiPSCs at 12 hr post-infection (MOI = 5). n = 3 independent experiments; data are presented as mean ± SD.(B) ELISA analysis of the concentrations of CCL4, CXCL8, IL-6, and TNF-α in the supernatants collected from the macrophage cultures at 24 hr post-infection (MOI = 5). n = 3 independent experiments; data are presented as mean ± SD; ^∗∗∗^p \< 0.001; one-way ANOVA.(C) ELISA analysis of the concentrations of CCL4, CXCL8, IL-6, and TNF-α in the supernatants collected from macrophage cultures with or without 3 hr of LPS (100 ng/mL) treatment after DENV, ZIKV^M^, and ZIKV^PR^ infection for 24 hr (MOI = 10). n = 3 independent experiments; data are presented as mean ± SD; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; one-way ANOVA.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

We further validated the differential induction of several well-characterized key pro-inflammatory cytokines (TNF-α and IL-6) and chemokines (CCL4 and CXCL8/IL-8) at the protein level. Significantly higher levels of these cytokines/chemokines were induced by DENV infection, compared with ZIKV, in both monocyte- and hPSC-derived macrophages ([Figure 6](#fig6){ref-type="fig"}B), although the infection rates of both viruses were almost the same in each group ([Figures S1](#mmc1){ref-type="supplementary-material"}H, S1I, and [S6](#mmc1){ref-type="supplementary-material"}C).

Given that these pro-inflammatory cytokines and chemokines gene expression are regulated by the NF-κB signaling pathway, we treated ZIKV- and DENV-infected macrophages with or without LPS, a strong activator of NF-κB signaling by binding to CD14 and TLR4 ([@bib61], [@bib45], [@bib44]), to further determine whether ZIKV can suppress pro-inflammatory cytokines and chemokines expression through inhibition of the NF-κB signaling pathway. LPS treatment strongly activated expression of IL-6, TNF-α, CCL4, and CXCL8, and viral infections generally interfered with this induction. However, the extent of the suppression was significantly stronger and broader in ZIKV-infected than in DENV-infected cells ([Figure 6](#fig6){ref-type="fig"}C), despite similar (∼90%) infection rates ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E). Taken together, these data suggest that the different abilities of the two viruses to activate the infected macrophages are not due to the difference in interferon production or signaling, but due to the difference in inhibition of the NF-κB signaling pathway.

ZIKV, but Not DENV, Disrupts the NF-κB-MIF Positive Feedback Loop in the Infected Macrophages {#sec2.5}
---------------------------------------------------------------------------------------------

To further verify whether ZIKV can suppress the NF-κB signaling pathway, we utilized an NF-κB luciferase reporter to monitor NF-κB signaling in mock-treated, LPS-treated, or virus-infected macrophages. LPS treatment and DENV infection strongly activated luciferase gene expression ([Figure 7](#fig7){ref-type="fig"}A). In contrast, luciferase expression in ZIKV-infected macrophages was at a much lower level ([Figure 7](#fig7){ref-type="fig"}A). To further confirm the inhibitory role of ZIKV in the NF-κB signaling pathway activation, we re-stimulated ZIKV- and DENV-infected macrophages with or without LPS. Compared with DENV, ZIKV infection significantly reduced the LPS-induced luciferase expression ([Figure 7](#fig7){ref-type="fig"}B), suggesting that ZIKV actively suppresses the activation of the NF-κB signaling pathway. To explore the relationship between the MIF and the NF-κB signaling pathways, we treated macrophages carrying the NF-κB luciferase reporter with human recombinant MIF protein. MIF increased NF-κB induced luciferase expression in a dose-dependent manner ([Figure 7](#fig7){ref-type="fig"}C), indicating that MIF has the ability to activate the NF-κB signaling pathway. In addition, treatment of macrophages with TNF-α, a cytokine induced by the NF-κB signaling pathway activation, increased MIF secretion ([Figure 7](#fig7){ref-type="fig"}D), consistent with the previous reports that the NF-κB signaling pathway and MIF activate each other, forming a positive feedback loop ([@bib9], [@bib31], [@bib52]). Based on these results, we hypothesized that ZIKV-mediated inhibition of NF-κB signaling underlies the mechanism by which ZIKV suppresses MIF production. To test this hypothesis, we treated DENV- and ZIKV-infected macrophages with LPS at 24 hr post-infection. A statistically significant difference was observed for the abilities of the two viruses to suppress LPS-activated MIF production, with ZIKV infection reducing MIF expression much more efficiently ([Figure 7](#fig7){ref-type="fig"}E). We next treated DENV- or ZIKV-infected macrophages with MIF to further confirm that ZIKV infection disrupts the NF-κB-MIF positive feedback loop. As shown in [Figure 7](#fig7){ref-type="fig"}F, compared with DENV, ZIKV significantly reduced NF-κB activity induced by MIF. Taken together, these data suggest that ZIKV suppresses NF-κB-MIF positive feedback by inhibiting the NF-κB signaling pathway ([Figure 7](#fig7){ref-type="fig"}G).Figure 7Inhibition of NF-κB-MIF Positive Feedback Loop in Infected Macrophages by ZIKV, but Not DENV(A) NF-κB luciferase reporter assay showing the relative NF-κB activities in macrophages infected by ZIKV or DENV (MOI = 10) for 24 hr. n = 3 independent experiments; data are presented as mean ± SD; ^∗∗∗^p \< 0.001; one-way ANOVA.(B) Relative NF-κB activities in macrophages with or without 3 hr of LPS (100 ng/mL) treatment after DENV, ZIKV^M^, or ZIKV^PR^ infection for 24 hr (MOI = 10). n = 3 independent experiments; data are presented as mean ± SD; ^∗∗∗^p \< 0.001; one-way ANOVA.(C) Relative NF-κB activities in macrophages induced by MIF at the indicated concentrations for 24 hr. n = 3 independent experiments; data are presented as mean ± SD; ^∗∗∗^p \< 0.001; one-way ANOVA.(D) ELISA analysis of the concentrations of MIF in the supernatants collected from macrophage cultures treated with TNF-α at the indicated concentrations for 24 hr. n = 3 independent experiments; data are presented as mean ± SD; ^∗^p \< 0.05; ^∗∗∗^p \< 0.001; one-way ANOVA.(E) ELISA analysis of the concentrations of MIF in the supernatants collected from macrophage cultures with or without 3 hr of LPS (100 ng/mL) treatment after DENV, ZIKV^M^, or ZIKV^PR^ infection for 24 hr (MOI = 10). n = 3 independent experiments; data are presented as mean ± SD; ^∗∗∗^p \< 0.001; one-way ANOVA.(F) Relative NF-κB activities in macrophages with or without 24 hr of MIF (20 ng/mL) or anti-MIF antibody (5 μg/mL) treatment at 24 hr post DENV or ZIKV^PR^ infection (MOI = 10). n = 3 independent experiments; data are presented as mean ± SD; ^∗∗^p \< 0.01; one-way ANOVA.(G) A proposed model of inhibition of NF-κB-MIF positive feedback loop by ZIKV. In macrophages, activation of the NF-κB signaling pathway enhances *MIF* expression which in turn further activates NF-κB signaling. ZIKV, but not DENV, disrupts the NF-κB-MIF positive feedback loop, by inhibiting the NF-κB signaling pathway, and decreases MIF production.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Viruses have developed sophisticated strategies to regulate NF-κB signaling activation by targeting different stages of the signaling cascade from early initiation stage to the final pro-inflammatory genes transcription ([@bib49]). We found that both DENV and ZIKV infection lead to phosphorylation and translocation of RELA/p65 ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B), suggesting that ZIKV may modulate NF-κB activation after RELA/p65 nuclear translocation at the transcription stage. Recently, it has been reported that ZIKV NS5 is able to inhibit the NF-κB signaling pathway ([@bib34]). Moreover, ZIKV NS5 is mainly localized in the nucleus ([Figure S7](#mmc1){ref-type="supplementary-material"}C). However, further investigations are needed to elucidate the molecular mechanism by which ZIKV regulates the NF-κB signaling pathway.

Discussion {#sec3}
==========

Macrophages are major effector cells in innate and adaptive immunity and play an important role in recognizing and eliminating invading pathogens. After recognition of pathogen-associated molecular patterns, such as LPS and dsRNA, macrophages become activated and secrete a broad array of pro-inflammatory cytokines (e.g., IL-1B, TNF-α, and IL-6) and chemokines (e.g., CCL4 and CXCL8/IL-8) that enhance host immune responses ([@bib45], [@bib44]). In the case of DENV infection, a "cytokine storm" formed by pro-inflammatory cytokines and chemokines following infection is a major event of dengue hemorrhagic fever ([@bib25]). We observed that both LPS treatment and DENV infection strongly activate pro-inflammatory cytokines and chemokines expression, consistent with the pathogenesis of dengue disease. It has been reported that significantly increased MIF secretion contributes to the severity of DENV infection ([@bib4]). In this study, we found that MIF production correlates with the inhibition of DENV-infected macrophage migration. While the increased pro-inflammatory cytokines and chemokines promote recruitment and activation of uninfected immune cells to the infection site, it is more advantageous to restrict the migration of DENV-infected macrophages to fight infection locally and limit the virus spread in human tissues. Conversely, ZIKV infection results in little induction of the pro-inflammatory cytokines and chemokines, which leads to a weaker immune response, and prolonged virus infection and persistence in body tissues. In addition, migration of infected macrophages can boost ZIKV\'s ability to cross physiological barriers and promote virus spread in the body. Of note, we observed that ZIKV only induced minimal cell death in the infected macrophages, which can contribute to its ability to disseminate in patients. In contrast to neural progenitor cells, the low cell death rate was also observed in ZIKV- or DENV-infected primary macrophages, DCs and endothelial cells ([@bib48], [@bib41], [@bib6], [@bib19], [@bib53], [@bib12]). The underlying mechanism of differential cell death sensitivity has not been well understood, but may have to do with the unique gene expression profiles in different cell types.

MIF was originally identified as a soluble factor that inhibits the random migration of macrophages and also has tautomerization enzymatic activity ([@bib5], [@bib8]), but its migration inhibitor property does not appear to be related to the enzymatic activity ([@bib27]). Although its migration inhibitory activity was reported many years ago, the mechanism for the MIF-induced migration inhibition has not been fully elucidated. MIF mediates its biological activities through different signaling pathways ([@bib8]). These signaling pathways activated by MIF may induce migration inhibition independently of, or combined with, NF-κB signaling activation. In addition, MIF plays a pivotal role in the inflammatory cascade and the innate immune response ([@bib8]). As part of the inflammatory cascade, MIF is rapidly released from virtually all leukocytes, including macrophages, and triggers the release of pro-inflammatory cytokines, including TNF-α, IL-1B, IL-6, and IL-8, via activation of the NF-κB signaling pathway ([@bib8], [@bib36]). Many pro-inflammatory cytokines, such as TNF-α, IL-5, and IL-1B, in turn stimulate *MIF* expression and secretion, forming a positive feedback loop ([@bib9], [@bib31], [@bib52], [@bib2], [@bib14], [@bib57], [@bib10]). At the transcriptional level, the 5′ regulatory region of *MIF* gene contains the consensus DNA-binding sequence for NF-κB ([@bib8]), and NF-κB proteins can directly regulate *MIF* gene expression ([@bib57], [@bib35], [@bib33], [@bib13]). In this study, we found that ZIKV, but not DENV, suppresses pro-inflammatory genes expression by inhibiting the NF-κB signaling pathway, which disrupts the NF-κB-MIF positive feedback loop and leads to the downregulation of MIF production. The MIF inhibition allows ZIKV-infected macrophages to maintain their migratory capacity in a longer time frame post-infection.

In previous studies, many viruses were found to block the NF-κB signaling pathway before RELA/p65 nuclear translocation. However, The E1A protein from human adenovirus 12, and NleH1 and NleH2 from *Escherichia coli* O157:H7 str. EDL9883, were reported to suppress NF-κB-dependent transcription at the post-nuclear translocation stage ([@bib49]). In the case of ZIKV infection, we discovered that RELA/p65 is phosphorylated and translocated to the nucleus after ZIKV infection. Although ZIKV NS5 is mainly localized in the nucleus and has been reported to be able to inhibit NF-κB activity ([@bib34]), the molecular mechanism by which ZIKV inhibits the NF-κB signaling pathway is still unclear. More efforts need to be made to better understand the pathogenesis of Zika.

In this study, we established a new macrophage model to investigate the yolk sac-derived macrophage-virus interaction. Yolk sac- and monocyte-derived macrophages differ with respect to the developmental origins and the developmental pathways ([@bib56], [@bib47]). It has been well documented that, before the establishment of the blood circulation, *Myb*-independent yolk sac progenitor cells give rise to tissue-resident macrophages, such as microglia, Langerhans cells, and Kupffer cells. In adults, yolk sac-derived tissue-resident macrophages are maintained by self-renewal and independent of circulating monocytes throughout adulthood. In contrast, *Myb*-dependent hematopoietic stem cells generate monocytes that give rise to relatively short-lived tissue-resident macrophages in adulthood ([@bib56], [@bib47]). In addition to the heterogeneity of macrophage lineage, circulating monocytes are also heterogeneous. Monocytes emerge as a highly plastic and dynamic cellular system in the blood after exiting the bone marrow and can be divided into several subsets based on the differential expression of cellular surface proteins and distinct physiological roles ([@bib20]). Together, all these increase the heterogeneity of macrophages and may result in the different virus infection efficiencies of monocyte- and yolk sac-derived macrophages.

We produced hPSC-derived macrophages using a protocol developed by Karlsson and coworkers ([@bib30], [@bib46], [@bib1]), which has recently been shown to produce macrophages in an *MYB*-independent, *RUX1*- and *SPI1* (*PU.1*)-dependent manner, suggesting that these macrophages are derived independent of hematopoietic stem cells and more related to yolk sac-derived tissue macrophages developmentally ([@bib55], [@bib7], [@bib16], [@bib60], [@bib24]). Considering that brain microglia are mainly established at the embryo stage ([@bib56], [@bib47]), ZIKV-infected microglia may facilitate virus spread in the fetal brain and contribute to fetal microcephaly.

Given the considerable technical challenge of obtaining the yolk sac-derived tissue-resident macrophages, our stem cell-derived macrophage model will be highly valuable for investigating macrophage-pathogen interactions. This macrophage model reveals important features of virus-host interactions that may be associated with the different pathogenesis of dengue and Zika diseases. The ability of this system to model prenatally established macrophages under both physiological and pathological conditions, such as infections and cancer immunity, has significant implications for human diseases research.

Experimental Procedures {#sec4}
=======================

Wound-Healing Assay {#sec4.1}
-------------------

Wound-healing assays of macrophages with or without virus infection were performed as described previously ([@bib51]). In brief, 3 × 10^5^ macrophages at day 5 were grown on coverslips in 12-well plates before being infected by ZIKV and DENV at an MOI of 10 or treated by 5 ng/mL LPS. At 4 hr post-infection, the cell monolayer was scratched by a sterile micropipette tip, followed by washes with PBS to remove the floating cells. Then the spent medium was put back into each cell sample. The images of the wound-healing process were taken immediately after the scratch, and 24 hr later, to monitor macrophage migration into the gap at ten points per scratch using light microscopy. The wound closure was quantified by measuring the distance covered by the migrated leading edge after scratching using ImageJ. The migratory abilities of macrophages treated by DENV, ZIKV, mock, or LPS were quantified by measuring the percentage of the gap closure in each sample from five independent experiments. For MIF neutralization assay, macrophages were infected by DENV as described above after being treated with 5 μg/mL anti-MIF polyclonal antibody (R&D Systems, catalog no. AF-289) for 30 min. The same amount of goat isotype polyclonal immunoglobulin antibody (Abcam) was used as the control. For MIF inhibition assay, macrophages were infected with or without ZIKV for 60 min before treated with or without 10 ng/mL MIF (R&D Systems, catalog no. 289-MF). At 4 hr post DENV or ZIKV infection, wound-healing assays were performed in all cell cultures as described above.

For detailed information regarding other experimental procedures, please see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.2}
--------------------

Statistical analyses were carried out using GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA). Unless mentioned otherwise, the results shown are representative of three independent experiments. All the data are presented as mean ± SD. The p values were calculated by one-way ANOVA with a Bonferonni test to make multiple pairwise comparisons between different groups or by unpaired two-tailed Student\'s t tests to compare the mean values of two groups: n.s., not significant; ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001.
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